RST-301

RST-301 is a small molecule NMDA receptor modulator specifically targeting the GluN2D subunit, currently under development by ReST Therapeutics for the treatment of Traumatic Brain Injury (TBI). As part of ReST Therapeutics' precision neuropsychiatry platform, RST-301 is designed to address NMDA receptor overactivation, which is a key pathological feature in various neurological disorders. By selectively inhibiting the GluN2D subunit, the drug aims to provide neuroprotection and facilitate recovery following brain trauma. The asset is currently in the discovery stage, leveraging the company's focus on subtype-specific NMDA receptor modulation to achieve therapeutic effects with reduced off-target neurological impact.